University of Leicester
Browse

Enhanced glucose processing in gestational diabetes diagnosis: effects on health equity and clinical outcomes.

Download (757.05 kB)
journal contribution
posted on 2025-01-07, 15:31 authored by Laura KusinskiLaura Kusinski

Objectives

Gestational diabetes is diagnosed using an oral glucose tolerance test (OGTT), which has limited accuracy, reproducibility and practicality. We assessed the effect of enhanced pre-analytical glucose processing upon glucose concentrations, gestational diabetes diagnosis, health equity and pregnancy outcomes, and if HbA1c was a suitable alternative.


Methods

We recruited pregnant women with ≥1 risk factor to a prospective observational cohort study of pregnancy hyperglycaemia, endocrine causes, lipids, insulin and autoimmunity (OPHELIA), from nine UK centres. During a 75 g antenatal OGTT (National Institute of Health and Care Excellence criteria), standard glucose processing was compared to enhanced glucose processing (storage on ice, rapid centrifugation, aliquoting and freezing <2.5 h).


Results

We recruited 1308 participants of mean (SD) age 31.5 years (5.0) and BMI 33.0 kg/m2 (6.8) of 82.5% white ethnicity, representative of the UK population. Enhanced glucose processing resulted in glucose levels ~0.6 mmol/L higher than standard glucose processing, increasing gestational diabetes diagnosis from 9% to 22%. Women with gestational diabetes on enhanced but not standard glucose processing (n = 165) were younger (31.9 vs. 33.2 years, p = 0.035), with a higher BMI (36.5 vs. 33.9 kg/m2; p = 0.003), different ethnic distribution (p = 0.025) and delivered more large-for-gestational age infants (37.0% vs. 22.3%; p = 0.006) compared to women with gestational diabetes on standard processing alone. HbA1c was not a suitable alternative predictor of gestational diabetes diagnosis (Area under receiver operator curve 0.74; 95% CI 0.68–0.79).


Conclusions

An OGTT with enhanced glucose processing would support more accurate, equitable diagnosis of gestational diabetes, but with increased diagnosis rates.

Funding

Diabetes UK

EFSD/Novo Nordisk Foundation Future Leaders Award. Grant Number: NNF19SA058974

NIHR Cambridge Biomedical Research Centre

NIHR Leicester Biomedical Research Centre

National Institute for Health Research

Find out more...

European Foundation for the Study of Diabetes

History

Author affiliation

College of Life Sciences Population Health Sciences

Version

  • VoR (Version of Record)

Published in

Diabetic Medicine

Publisher

Wiley

issn

0742-3071

eissn

1464-5491

Copyright date

2024

Available date

2025-01-07

Language

en

Deposited by

Dr Laura Kusinski

Deposit date

2024-12-17

Usage metrics

    University of Leicester Publications

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC